Omonigho Aisagbonhi
Gerald P. Morris- Department of Pathology, University of California San Diego, San Diego, CA, United States
Preeclampsia is a pregnancy-induced hypertensive disorder, the pathophysiology of which includes underlying maternal cardiovascular disease, deficient spiral artery remodeling during placenta development, and inflammatory immune responses at the maternal-fetal interface. Human leukocyte antigens (HLA) are major histocompatibility complex molecules essential for the recognition of foreign antigens that is central to immune defense against pathogens and critical determinants for the immune system discriminating between self and non-self tissues, such as in transplantation. Pregnancy represents a naturally existing “transplantation”, where the maternal immune system must be immunologically tolerant to the developing fetus which is 50% allogeneic. It is then unsurprising that HLA also influence normal pregnancy and pregnancy complications including preeclampsia. Here we review the role of classical and non-classical HLA molecules in influencing normal physiologic function during pregnancy and describe the association of HLA with pathophysiology in preeclampsia.
Introduction
Pregnancy can be viewed as a naturally-occurring allograft, with a semi-allogeneic fetus requiring access to maternal circulation for provision of nutrients and oxygenation during development. In contrast to the robust immune responses typically elicited by allogeneic stimulation, the maternal immune system does not mount an inflammatory response to the fetus under normal physiology. This immunologic tolerance is facilitated by the development and function of the placenta. The placenta is a fetal organ that develops to become the interface between which maternal and fetal cells interact (Figure 1). Placental trophoblast cells are the primary fetal cells directly exposed to the maternal immune system (Moffett and Loke, 2006). Villous trophoblasts, comprised of an inner layer of cytotrophoblasts and an outer layer of syncytiotrophoblasts, are directly in contact with maternal blood and maternal systemic immune system at the intervillous space. Extravillous trophoblasts (EVTs) migrate from the cytotrophoblast shell through decidual stroma and remodel maternal decidual spiral arteries into low resistance, high conductance dilated vessels without smooth muscle, which enables optimal flow of blood for oxygen exchange to support placental and fetal growth (Burton, et al., 2009). Interaction between fetal trophoblast cells and maternal immune cells at the placental interface are essential for regulating these remodeling processes and maintaining maternal immunologic tolerance to the fetus.
FIGURE 1. HLA molecules in normal pregnancy. HLA-G-expressing syncytiotrophoblasts interact with the maternal systemic immune system at the intervillous space to induce tolerance. EVTs express HLA-C, -E, -F and–G and interact with maternal decidual immune cells and endothelial cells to induce tolerance and remodel spiral arteries. Optimal placentation occurs when HLA-C engages activating KIR receptors (e.g. KIR2DS1/5) resulting in release of chemokines and cytokines (e.g. GM-CSF and IL-8) that enhance EVT invasiveness. HLA-C also plays a role in pathogen recognition and antigen presentation.
Preeclampsia
Preeclampsia is a pregnancy-induced hypertensive disorder defined as new-onset hypertension and proteinuria or new-onset hypertension and end-organ (heart, lung, brain, kidney, liver) dysfunction, occurring between 20 weeks of gestation and 6 weeks post-partum (Bouter and Duvekot, 2020). Preeclampsia is relatively common, affecting as many as 4–10% of all pregnancies worldwide. In the most severe cases, preeclampsia can be fatal, with maternal end-organ failure. Despite the significant risks of morbidity and mortality from preeclampsia, no singularly effective cure exists, with treatment relying on early detection and administration of antihypertensive medications to bridge the mother and fetus to delivery. The efficacy of this approach is limited, with preeclampsia persisting as one of the five leading causes of maternal mortality worldwide (Say, et al., 2014). The incidence and clinical outcomes in preeclampsia vary by geographic region and maternal ethnicity, suggesting both environmental and genetic components contribute to the pathophysiology.
Emerging evidence suggests that rather than having a single cause, preeclampsia is a multifactorial syndrome that can result from multiple distinct pathophysiologic processes. Using unsupervised clustering of aggregate microarray datasets (first in 173 patient samples, including 77 with preeclampsia and later in a larger dataset of 330 samples), 3 molecular clusters/subclasses of preeclampsia have been proposed (Table 1) (Leavey, et al., 2015; Leavey, et al., 2016). Preeclampsia samples in cluster 1 showed normal placental histopathology and the birthweights of delivered infants were appropriate for gestational age. At the molecular level, there was no significant difference in gene expression by cells in the placenta between preeclampsia cases from cluster 1 and controls without preeclampsia. Thus, it was reasoned that underlying maternal factors, unrelated to the placenta, are the likely etiology of preeclampsia in cluster 1 patients. Clusters 2 and 3 had more clinically significant presentations, with higher maternal blood pressures, higher proteinuria and uric acid levels. Placentas in cluster 2 demonstrated classic preeclampsia-associated findings (small for gestational age, distal villous hypoplasia, with syncytial knots and infarcts) and were significantly more likely to be associated with infants that were small for gestational age (SGA) and/or had a clinical diagnosis of intrauterine growth restriction. Genes involved with hormone secretion, response to nutrient, redox activity and response to hypoxia/angiogenesis were over-represented in cluster 2. Preeclampsia placentas in cluster 3 showed increased rates of massive perivillous fibrin deposition, a placental lesion associated with maternal anti-fetal rejection (Romero, et al., 2013; Gundogan, et al., 2010), and increased expression of genes associated with allograft rejection, immune and inflammatory responses.
TABLE 1. Summary of clinical, pathologic and molecular findings in the 3 proposed etiologic clusters of PE–maternal, canonical and immunologic (Leavey, et al., 2016).
Based on these findings, three etiologic categories for PE have been proposed—1) maternal preeclampsia caused by maternal factors unrelated to the placenta; 2) canonical preeclampsia caused by deficient spiral artery remodeling and 3) immunologic preeclampsia caused by maternal-fetal incompatibility. Considering preclampsia as a syndrome with at least 3 different etiologic categories begins to explain why the disease has different clinical (mild vs severe; early vs late-onset) and pathologic manifestations (small placenta with evidence of maternal vascular malperfusion vs increased perivillous fibrin deposition with or without an associated chronic villitis, vs normal sized placenta without significant pathology) (Roberts, et al., 2021). Within this context of multi-modal pathophysiology it becomes possible to consider the influence of genetics on preeclampsia.
Human Leukocyte Antigen
The human leukocyte antigen (HLA) system is a cluster of >100 genes regulating immune function located on the short arm of chromosome 6p21.3 (Shiina, et al., 2009). Most notably, the HLA locus contains genes encoding the HLA genes, human orthologs of Major Histocompatibility Complex (MHC) genes. HLA/MHC proteins’ primary function is to present antigens to T lymphocytes, enabling recognition of foreign antigens by the cellular arm of the adaptive immune system (Neefjes, et al., 2011). The defining genes of the HLA locus include the classical HLA class Ia genes HLA-A, HLA-B, and HLA-C, encoding the HLA-A, HLA-B, and HLA-C proteins which present peptide antigens to CD8+ cytotoxic T cells, and the HLA class II genes HLA-DRA1, HLA-DRB1, HLA-DRB3/4/5, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 which encode the proteins forming the HLA-DR, HLA-DQ, and HLA-DP molecules that present peptide antigens to CD4+ helper T cells, including immunosuppressive regulatory T cells (Tregs). The genes encoding the classical HLA molecules are the most genetically diverse genes in the human genome, with over 25,000 defined allelic variants (Robinson, et al., 2020), with even more alleles being identified regularly. The extensive nucleotide sequence variability translates to protein polymorphisms that influence the ability of HLA molecules to bind and present antigens as well as interact with leukocyte antigen receptors. This diversity underpins the robust immune responses of T lymphocytes to allogeneic tissues, with HLA protein sequence diversity both directly affecting the interaction of T cell antigen receptors with the HLA molecule and indirectly stimulating T cell responses via differential presentation of endogenous tissue antigens (Felix and Allen, 2007).
In addition to presentation of peptide antigens to T lymphocytes, HLA-C (and some HLA-A, and HLA-B molecules, though these are not expressed by EVTs) is involved in the regulation of NK cell activity. Class I HLA molecules interact with NK cells in a (mostly) peptide-independent manner through a combination of activating and inhibitory signals initiated by the binding of Killer Immunoglobulin Receptor (KIR) molecules (Parham, 2005). These interactions involve multiple different KIR molecules, each with differential ability to interact with HLA-C and other ligands, and each containing different intracellular signaling motifs. There are 17 identified KIR genes, each of which have 30–230 known genetic allotypes, located in the Leukocyte Receptor Complex (LRC) region on chromosome 19q13.4 (Barrow and Trowsdale, 2008; Robinson, et al., 2013). KIR genes can be broadly divided into activating “DS” receptors, containing short intracellular domains with activating signaling motifs, and inhibitory “DL” receptors, containing longer intracellular domains with inhibitory signaling motifs. An individual’s KIR gene repertoire varies both by allelic variation as well as gene content, with the presence or absence of specific KIR genes being the primary determinant of the ability of NK cells to interact with HLA-C. NK cell recognition of HLA-C is determined by which amino acid is expressed at position 80 of the HLA-C molecule. In terms of KIR interaction, HLA-C molecules are divided into 2 groups, with the HLA-C1 group having asparagine (Asn) at position 80 while the HLA-C2 group contains lysine (Lys) at position 80. HLA-C1 group molecules interact with activating KIR2DS2 and inhibitory KIR2DL2 and KIR2DL3 receptors while HLA-C2 group molecules interact with activating KIR2DS1 and inhibitory KIR2DL1 receptors (Parham, 2005).
Beyond the classical HLA molecules, the HLA-E, HLA-F, and HLA-G genes (HLA class Ib genes) encode non-classical HLA class I proteins HLA-E, HLA-F and HLA-G which can present a relatively limited set of peptide and non-protein antigens to leukocytes, including T lymphocytes, non-classical T cells, and Natural Killer (NK) cells (Carosella, et al., 2015; Grant, et al., 2020; Persson, et al., 2020). Additionally, some interactions between non-classical HLA molecules and leukocyte receptors are antigen-independent, with recognition of the HLA molecule by receptors being deterministic for inducing immune cell response. The interactions between non-classical HLA molecules and their associated receptors can provide either stimulatory or inhibitory signals to immune cells, depending on the specific HLA-receptor combination. In contrast to classical HLA genes, the genes encoding non-classical HLA molecules have limited genetic diversity (Robinson, et al., 2020). The effects of these limited polymorphisms on interaction with leukocyte receptors is incompletely defined, though there is evidence that this genetic variation, particularly when located in untranslated regulatory regions, can result in differences in non-classical HLA expression (Gobin and van den Elsen, 2000; Strong, et al., 2003; Hviid, et al., 2003). This genetic diversity can result in selective activation of immune cells in response to allogeneic cells, either by interaction with allogeneic HLA molecules that provide a stimulatory signal or via the absence of interactions required to provide inhibitory signals.
Human Leukocyte Antigen in Normal Pregnancy
Interactions of HLA molecules with T cells and NK cells are essential determinants of immune function and discrimination between self- and non-self. As such, HLA molecules have a critical role in the interactions between fetal trophoblasts and maternal immune cells. The maternal immune system has to maintain a balance between immunologic tolerance for the semi-allogeneic fetus and the ability to respond to pathogens to prevent infection. HLA-C and the non-classical HLA class Ib molecules are important for normal pregnancy, where they play roles in modulating maternal immune responses to the semi-allogeneic fetus, spiral artery remodeling and pathogen recognition. HLA expression differs between villous trophoblasts and EVTs (Figure 1). While neither villous trophoblasts nor EVTs normally express HLA-A, HLA-B, or HLA class II molecules, EVTs express HLA-C, HLA-E, HLA-F and HLA-G while villous trophoblasts only express soluble forms of HLA-G (Ishitani, et al., 2003; Apps, et al., 2009). It is unclear whether trophoblast expression of HLA molecules changes during gestation. Increased expression of HLA-E and HLA-F by EVTs from the first to second to third trimester has been observed (Shobu, et al., 2006); however, a contrasting study found HLA-E expression limited to the first trimester and expression of HLA-C, HLA-F and HLA-G decreased as gestation progressed (Hackmon, et al., 2017). This restricted and potentially dynamic expression of HLA molecules influences their ability to regulate immune cell function at the maternal-fetal interface.
Placental Human Leukocyte Antigen and Protective Immune Responses
The most obvious physiologic function of HLA molecules at the maternal-fetal interface is to present antigens from infectious pathogens, enabling the maternal immune system to mediate protective cellular immune responses. Fetal EVTs, like all other mature cells, co-dominantly express both chromosomal copies of HLA genes. Thus, the semi-allogeneic fetal EVTs express maternally-derived HLA-C, enabling self-MHC-restricted maternal T cells to respond to presented foreign antigens. HLA-C expressed by fetal EVT are also able to present pathogen-derived peptide antigens to maternal NK cells via interactions with KIR2DS1, KIR2DS2, and KIR2DS4 activating receptors, stimulating NK cell-mediated responses to infection (Crespo, et al., 2016; Naiyer, et al., 2017; Sim, et al., 2019). HLA-E is also capable of presenting a limited set of pathogen-derived antigens, including peptides derived from cytomegalovirus (CMV) and Human immunodeficiency virus (HIV), which can cause significant morbidity and mortality in neonates (Grant, et al., 2020). HLA-E is capable of stimulating NK cells via the activating KIR2DS1 and NKG2C receptors (Braud, et al., 1998; Lee, et al., 1998). HLA-F is similarly capable of stimulating NK cells via KIR3DS1 (Garcia-Beltran, et al., 2016; Burian, et al., 2016). Thus, despite the restricted set of HLA molecules expressed by trophoblasts, the maternal immune system is capable of detecting infection and mediating innate and adaptive cellular immune responses. Co-dominant expression of HLA-C alleles also results in expression of likely genetically dissimilar paternal HLA-C by EVTs, which presents the challenge of potential alloreactive responses by maternal immune system.
Placental Human Leukocyte Antigen and Inhibition of Inflammatory Immune Responses
The absence of immunologic rejection of the semi-allogeneic fetus is not due to a lack of ability of the maternal immune system to recognize the foreignness of fetus. Indeed, multiple studies have demonstrated the existence of fetal antigen-reactive T cells, both at the placental interface and in circulation (Tilburgs, et al., 2010; Lissauer, et al., 2012; van der Zwan, et al., 2018). Inhibition of inflammatory immune responses and promotion of immunologic tolerance at the maternal-fetal interface instead relies upon multiple physiologic mechanisms. Expression of the inhibitory co-stimulatory PD-L1 (Nagamatsu, et al., 2009) by EVTs, production of the immunosuppressive metabolite indoleamine-2-3-dioxygenase (IDO) (Munn, et al., 1998), and expression of immunosuppressive cytokines such as IL-10 and TFG-β (Guzeloglu-Kayisli, et al., 2009) all act to directly inhibit the activity of inflammatory and cytotoxic lymphocytes in the placental microenvironment. The non-classical HLA class Ib molecules HLA-G, and HLA-E have also been reported to directly inhibit cytotoxic and pro-inflammatory T cells and NK cells at the placenta. HLA-G interacts with decidual NK cells, T cells, B cells, and myeloid cells via KIR2DL4 receptor on NK cells, ILT2 receptor on T cells, B cells, and some NK cells, and ILT4 receptor on myeloid cells (Colonna, et al., 1998; Rajagopalan and Long, 1999; Shiroishi, et al., 2006). HLA-G is capable of inhibiting antigen-specific and alloreactive cytotoxic T cell responses in vitro (Le Gal, et al., 1999; Kapasi, et al., 2000). Expression of HLA-G is also sufficient to prevent NK cell-mediated cytolysis (Chumbley, et al., 1994; Pazmany, et al., 1996). HLA-G can also mediate immunosuppressive function in the absence of direct cell-cell contact. HLA-G is unique among HLA molecules, with the existence of alternatively spliced mRNA forms which produce seven different HLA-G protein isoforms (Ishitani and Geraghty, 1992; Fujii, et al., 1994). The isoforms include conventional membrane-bound G1-G4 isoforms and G5-G7 secreted soluble (sHLA-G) proteins. sHLA-G molecules have inhibitory effects on T cells and NK cells similar to those of membrane-bound HLA-G. sHLA-G is produced by trophoblasts (Solier, et al., 2002), suggesting a role for HLA-G in regulating maternal immune responses. Indeed, both membrane-bound or soluble HLA-G inhibits CD4+ and CD8+ T cell responses and NK cell-mediated cytolysis of allogeneic cytotrophoblasts in vitro, indicating the functional relevance of this inhibition at the maternal/fetal interface (Rouas-Freiss, et al., 1997; Kostlin, et al., 2017). HLA-E has been shown to be similarly protective against NK cell-mediated lysis via interactions with activating NKG2C receptor on NK cells, inhibitory CD94/NKG2A receptors on NK cells, and CD8 on T cells (Braud, et al., 1998; Lee, et al., 1998).
Trophoblast-expressed HLA-G also influences the generation and persistence of CD4+FoxP3+ Tregs. Tregs are important mediators of immunologic tolerance, capable of regulating the responses of immune cells and preventing pathologic inflammatory responses (Sakaguchi, et al., 2020). The regulatory function of maternal Tregs is essential at the maternal/fetal interface to prevent maternal alloimmune response and immunologic rejection of the fetus (Tsuda, et al., 2021). Maternal Tregs are specific for fetal antigens and activated via their antigen receptor by peptide antigens presented by HLA class II molecules. While trophoblasts do not express HLA class II molecules, maternal Tregs are exposed to fetal antigens presented by HLA II molecules on antigen-presenting cells such as dendritic cells and macrophages in the placental microenvironment. The relative importance of Tregs in suppressing maternal alloreactive immune responses at the maternal-fetal interface can be demonstrated by the observation that Tregs are increased in pregnancies where maternal and fetal HLA-C genotypes are mismatched (Tilburgs, et al., 2009). This suggests that the Treg response must be increased as a necessary response to increased allogeneic stimulation by the fetus. Several studies have indicated that placental tissue, specifically EVTs expressing HLA-G, promote differentiation of CD4+ T cells into Tregs (LeMaoult, et al., 2004; Tilburgs, et al., 2015; Svensson-Arvelund, et al., 2015). This Treg induction is associated with inhibition of alloreactive T cell responses, demonstrating the potential mechanism by which fetal HLA-G contributes to immunologic tolerance via Treg induction.
Human Leukocyte Antigen and Placental Development
A more unique role for HLA molecules in pregnancy occurs during the process of physiologic conversion, whereby maternal spiral arteries are remodeled into low-resistance, high-conductance vessels, which is necessary for the growth and function of the placenta. During this process, EVTs interact with local maternal decidual NK cells, and stimulate them to aid in tissue remodeling during fetal development. NK cell activity is critical during physiologic conversion, and is regulated by interaction with HLA-C, HLA-G, and HLA-E. Interactions between HLA-C and activating KIRs stimulate NK cells to secrete chemokines and cytokines such as GM-CSF, IL-8, and interferon-inducible protein 10, that promote trophoblast migration and ultimately contribute to spiral artery remodeling during normal placentation (Hanna, et al., 2006; Xiong, et al., 2013). HLA-G also promotes NK cell activity contributing to trophoblast invasion and spiral artery remodeling. sHLA-G5 stimulates trophoblast invasion in vitro by binding KIR2DL4 and LILRB1 (a.k.a. ILT2), activating the ERK signaling pathway and increasing production of tissue remodeling-associated proteases uPA and MMPs as well as proangiogenic cytokines and chemokines (Rajagopalan, et al., 2006; Guo, et al., 2013; Fu, et al., 2017; Gamliel, et al., 2018). During spiral artery remodeling, HLA-G may also interact with endothelial cells directly, as HLA-G1 induced endothelial cell apoptosis via binding endothelial CD160 receptor (Fons, et al., 2006). Roles for HLA-E and HLA-F in regulation of NK cell activity during physiologic conversion have not been demonstrated, though both HLA-E and HLA-F are expressed by invading EVTs and interact with receptors on NK cells.
Human Leukocyte Antigen in Placental Pathology
Human Leukocyte Antigen in Maternal Preeclampsia
The 3 pathophysiologic clusters of preeclampsia proposed based on placental gene expression include preeclampsia resulting from maternal factors, deficient placental development, and immunologic incompatibility (Leavey, et al., 2015; Leavey, et al., 2016). Of these categories, maternal preeclampsia, considered as a consequence of underlying maternal factors such as cardiovascular disease and obesity, is the least likely to be directly influenced by placental HLA genetics. However, it should be noted that some underlying maternal autoimmune diseases that increase risk for preeclampsia have susceptibilities that have been linked to HLA. An example is systemic lupus erythematosus (SLE), which has been associated with a 1.91 relative risk for preeclampsia in a meta-analysis (Bundhun et al., 2017). Increased SLE susceptibility has been linked to HLA-DRB1*15 alleles across multiple ethnic populations (Selvaraja et al., 2022). Ankylosing spondylitis, a disease whose susceptibility is strongly linked to HLA-B*27 (Ebrahimiadib et al., 2021) has similarly been associated with poor pregnancy outcomes (Jakobsson et al., 2016). Other autoimmune diseases such as type 1 diabetes mellitus and rheumatoid arthritis also have increased risks conferred by HLA class II haplotypes (Ebrahimiadib et al., 2021; Enczmann et al., 2021). Nevertheless, as HLA-B and class II HLA molecules are not normally expressed by placental trophoblasts, the mechanism by which maternal autoimmune diseases lead to poor pregnancy outcomes like preeclampsia and preterm birth needs to be further elucidated.
Human Leukocyte Antigen in Immunologic Preeclampsia/Maternal-Fetal Incompatibility or Tolerance Failure
The concept of the fetus as a semi-allogeneic graft is based upon the fact that the fetus is 50% of maternal genetic origin and 50% paternal genetic origin. HLA genes are typically inherited en bloc as a unit containing all of the genes from a single chromosome 6p21 region, inheriting 1 maternal set or haplotype and 1 paternal haplotype. Given the extensive genetic diversity of HLA genes, a fetus is expected to be genetically dissimilar from the mother for HLA genes, most commonly haploidentical or mismatched for 1 allele of each of the classical HLA genes. The influence of maternal-fetal HLA mismatches in immunologic preeclampsia is unclear. Retrospective analysis of oocyte donation pregnancies found pregnancy losses and preeclampsia were associated with increased numbers of HLA gene mismatches between maternal-fetal pairs (Lashley, et al., 2015; van Bentem, et al., 2020). However, studies on HLA mismatches and preeclampsia in spontaneously conceived pregnancies have yielded varied and sometimes contradictory findings with no clear evidence for an association between HLA dissimilarity between the mother and fetus and the incidence of preeclampsia (Hoff, et al., 1992; Biggar, et al., 2010; Triche, et al., 2014; Van’t Hof et al., 2021).
A lack of clear association between HLA mismatches and preeclampsia may reflect limitations in the analyses performed. Separation of the effects of individual HLA genes on preeclampsia has similarly mixed results, with demonstration of selective influence by either HLA class I (Lashley, et al., 2015; van’t Hoff, et al., 2021) or HLA class II (Triche, et al., 2014; van Bentem, et al., 2020; van’t Hoff, et al., 2021) genes. Of the class I genes, only HLA-C has been demonstrated to have statistically confident influence independent from other HLA mismatches (van’t Hoff, et al., 2021). This likely reflects the fact that fetal trophoblast cells do not express HLA-A or HLA-B, but do express HLA-C, making it the only classical HLA class I molecule available to interact with maternal immune cells. Dissection of the effect of HLA-C mismatches indicates that fetal expression of paternal alleles in the C2 group are associated with increased risk for preeclampsia and placental immune lesions (Hiby, et al., 2004; Hiby, et al., 2010; Schonkeren, et al., 2012; Larsen, et al., 2019; van’t Hoff, et al., 2021). Presumably, this association is driven by differential interaction of C2 group molecules with either activating or inhibitory KIR molecules. However, this association is complicated by population-specific variability in maternal KIR genetics, which determine the repertoire of NK cell receptors available to interact with HLA-C molecules. Maternal inhibitory KIR AA genotype has been shown to be associated with increased risk of preeclampsia in Europeans from the United Kingdom, East-Africans and Han Chinese and maternal activating KIR B genotypes (KIR2DS1 in Europeans and Ethiopians, KIR2DS5 in East Africans and KIR2DS2/3/5 in Han Chinese) have been shown to be protective against preeclampsia (Hiby et al., 2004; Hiby et al., 2010; Long et al., 2015; Nakimuli et al., 2015; Kelemu et al., 2020). However, a Danish study of fetal HLA-C and maternal KIR genotypes in severe preeclampsia found no significant association between maternal KIR AA and fetal HLA-C2 alleles and severe preeclampsia risk (Larsen et al., 2019). Studies evaluating the expression patterns of HLA-C and activating versus inhibitory KIRs in the placentas of patients with mild vs severe preeclampsia in contrast to those without preeclampsia across different ethnic groups may be informative.
Potential effects for maternal/fetal HLA class II mismatches, specifically HLA-DRB1 and HLA-DQB1, with preeclampsia are less straightforward, as neither villous nor extravillous trophoblasts normally express HLA class II molecules. However, aberrant expression of HLA-DR by syncytiotrophoblasts has been observed in placentas of women with preeclampsia (Small, et al., 2017; Tersigni, et al., 2018). This likely reflects an expected physiologic response to placental inflammation, as MHC class II gene expression is regulated by the Class II Transcription Activator (CIITA) transcription factor, which is upregulated by the inflammatory cytokine interferon γ (Steimle, et al., 1994). The pathophysiologic consequences of this dysregulation are undefined, though it may represent a mechanism for aberrant stimulation of CD4+ helper T cells or dysregulation of Treg function.
The non-classical HLA class I molecules HLA-F and HLA-G have also been identified as potentially dysregulated in preeclampsia. While both HLA-F and HLA-G have relatively limited genetic diversity compared to classical HLA genes, both have identified expression variants, either via prematurely terminating null variants or regulatory elements in non-coding regions (Robinson, et al., 2013). While reduced expression variants of HLA-F have not been associated with preeclampsia, the rs1362126, rs2523405, and rs2523393 variants have been associated with reduced fertility (Langkilde, et al., 2020). The importance of HLA-F in inhibiting NK cell-mediated cytotoxic responses was postulated as a potential mechanism for this association. The influence of HLA-G on preeclampsia is better described. Multiple studies have observed decreased HLA-G expression, both by fetal cells in the placenta as well as soluble forms in circulation, in patients with preeclampsia is associated with impaired maternal-fetal immune tolerance (Yie, et al., 2004; Steinborn, et al., 2007; Vianna, et al., 2016). Decreased HLA-G expression in preeclampsia has been associated with reduced frequencies of regulatory T cells and increased expression of pro-inflammatory cytokines (Vianna, et al., 2016; Wedenoja, et al., 2020). The mechanism by which HLA-G is decreased in preeclampsia is undefined. A number of studies have suggested that a fetal 14bp insertion/deletion polymorphism may account for decreased HLA-G expression and increased preeclampsia risk (O’Brien, et al., 2001; Hylenius et al., 2004; Hviid, et al., 2004; Rokhafrooz, et al., 2018), though other studies have not found the same association (Pabalan, et al., 2015; Nilsson, et al., 2016). Down-regulation of HLA-G expression via hypermethylation of the promoter has been proposed as an alternative mechanism for downregulation of HLA-G in preeclampsia (Tang, et al., 2015). Epigenetic dysregulation of HLA-G is of significant interest as it represents a mutable and potentially actionable target for intervention.
Human Leukocyte Antigen in Deficient Spiral Artery Remodeling
Defective spiral artery remodeling during physiologic conversion is well-recognized as an important etiology of preeclampsia (Brosens, et al., 1972; Lim, et al., 1997; Fisher, 2015). As described above, spiral artery remodeling is dependent on interactions between HLA-C, HLA-G, and HLA-E molecules on EVTs and receptors on decidual NK cells and vascular endothelial cells. The association of fetal HLA-C2 genotypes with preeclampsia has been proposed to result from a lack of appropriate NK cell activation during spiral artery remodeling (Hiby, et al., 2004; Hiby, et al., 2010; Nakimuli, et al., 2015; Long, et al., 2015). Reduced expression of HLA-G by EVTs has been similarly associated with preeclampsia (Colbern, et al., 1994; Hara, et al., 1996; Goldman-Wohl, et al., 2000). However, it is difficult to disentangle the observed effects of HLA-C and HLA-G in spiral artery remodeling from their roles in inhibiting inappropriate inflammatory responses in the majority of studies to date. An interesting possibility is that the differential roles (anti-inflammatory versus spiral artery remodeling) may be related differential interactions with maternal immune, stromal and endothelial cells and their various receptors.
Anti-Human Leukocyte Antigen Antibodies and Preeclampsia
Circulating antibodies directed against paternal-derived HLA antigens can be detected in normal pregnancies (first described by Van Rood et al., 1958 and Payne and Rolfs, 1958). However, whether these antibodies contribute to pregnancy complications like preeclampsia is controversial. A meta-analysis found no consistent effect of anti-HLA class I or class II antibodies on pregnancy outcome (Lashley et al., 2013).
Summary
This review has summarized current understanding of the roles HLA molecules play in pregnancy and preeclampsia (Figures 1, 2; Table 2). Given the central role of HLA molecules in immune function, their near-ubiquitous expression, and the considerable amount of genetic diversity in HLA genes directly affecting HLA function, it is not surprising that HLA is commonly identified as associated with diseases having known genetic factors. Of the HLA molecules (HLA-C, HLA-E, HLA-F, and HLA-G) expressed by placental trophoblasts, HLA-C and HLA-G are the most studied, with well-defined roles both in ensuring maternal tolerance of the semiallogeneic fetus and in tissue remodeling required for spiral artery development for adequate perfusion of the developing placenta. The functions of HLA-E and HLA-F in pregnancy and preeclampsia are less well-described and warrant further investigation.
FIGURE 2. HLA molecules in preeclampsia. HLA-G levels are decreased in preeclampsia which evidence suggest result in defects in tolerance induction and spiral artery remodeling. Though disputed by some studies, most studies suggest that HLA-C engaging inhibitory KIR receptors on NK cells (such as KIR2DL1) also leads to defects in spiral artery remodeling as failed NK cell release of pro-migratory chemokines and cytokines limits EVT invasion. The roles of HLA-E and HLA-F in preeclampsia need to be investigated further.
TABLE 2. Summary of the roles HLA-C, E, F and G play in normal pregnancy and how their dysregulation contributes to preeclampsia.
A significant limitation of the studies on maternal/fetal HLA mismatches to date is the treatment of all dissimilarity at the genetic level as equivalent. However, there may be distinctions among these mismatches, with certain differences having differential functional impact. The classification of HLA-C mismatches into C1 and C2 groups is an example of functional classification of mismatches. However, HLA-C1/C2 classification only relates to regulation of NK cells and does not address the canonical role of classical HLA molecules in the presentation of antigens to T cells. We propose that it may be informative for future analyses to examine HLA differences in this function, using measures of structural dissimilarity and antigen binding (Sidney, et al., 2008; Chowell, et al., 2019). Similarly, there may be maternal HLA genetic factors (such as HLA class II genotypes) influencing the maternal immune response that have yet to be appreciated.
The recent proposal classifying preeclampsia as resulting from 3 distinct pathophysiologic pathways (Leavey, et al., 2015; Leavey, et al., 2016) also raises the possibility that any influence of HLA genotypes on preeclampsia may be obfuscated by not having separated analyses into more well-defined categories. Indeed, an absence of an effect of genes regulating immune function such as HLA would not be surprising in non-immune mediated pathology, and thus may be underestimated by not distinguishing immune-mediated and non-immune-mediated mechanisms for preeclampsia. We propose that this distinction in future studies may more clearly reveal genetic associations and functional roles for the HLA genes and help define genetic risk factors in preeclampsia.
Author Contributions
OA and GM were involved in the conception, research, and writing of this manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Apps, R., Murphy, S. P., Fernando, R., Gardner, L., Ahad, T., and Moffett, A. (2009). Human Leucocyte Antigen (HLA) Expression of Primary Trophoblast Cells and Placental Cell Lines, Determined Using Single Antigen Beads to Characterize Allotype Specificities of Anti-HLA Antibodies. Immunology 127, 26–39. doi:10.1111/j.1365-2567.2008.03019.x
Barrow, A. D., and Trowsdale, J. (2008). The Extended Human Leukocyte Receptor Complex: Diverse Ways of Modulating Immune Responses. Immunol. Rev. 224, 98–123. doi:10.1111/j.1600-065x.2008.00653.x
Biggar, R. J., Poulsen, G., Ng, J., Melbye, M., and Boyd, H. A. (2010). HLA Antigen Sharing between Mother and Fetus as a Risk Factor for Eclampsia and Preeclampsia. Hum. Immunol. 71 (3), 263–267. doi:10.1016/j.humimm.2010.01.006
Bouter, A. R., and Duvekot, J. J. (2020). Evaluation of the Clinical Impact of the Revised ISSHP and ACOG Definitions on Preeclampsia. Pregnancy Hypertens. 19, 206–211. doi:10.1016/j.preghy.2019.11.011
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., et al. (1998). HLA-E Binds to Natural Killer Cell Receptors CD94/NKG2A, B and C. Nature 391, 795–799. doi:10.1038/35869
Brosens, I. A., Robertson, W. B., and Dixon, H. G. (1972). The Role of the Spiral Arteries in the Pathogenesis of Preeclampsia. Obstet. Gynecol. Annu. 1, 177–191.
Bundhun, P. K., Soogund, M. Z. S., and Huang, F. (2017). Impact of Systemic Lupus Erythematosus on Maternal and Fetal Outcomes Following Pregnancy: a Meta-Analysis of Studies Published between Years 2001-2016. J. Autoimmun. 79, 17–27. doi:10.1016/j.jaut.2017.02.009
Burian, A., Wang, K. L., Finton, K. A. K., Lee, N., Ishitani, A., Strong, R. K., et al. (2016). HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-like Receptor KIR3DS1. PLoS ONE 11, e0163297. doi:10.1371/journal.pone.0163297
Burton, G. J., Woods, A. W., Jauniaux, E., and Kingdom, J. C. P. (2009). Rheological and Physiological Consequences of Conversion of the Maternal Spiral Arteries for Uteroplacental Blood Flow during Human Pregnancy. Placenta 30, 473–482. doi:10.1016/j.placenta.2009.02.009
Carosella, E. D., Rouas-Freiss, N., Roux, D. T.-L., Moreau, P., and LeMaoult, J. (2015). HLA-G. Adv. Immunol. 127, 33–144. doi:10.1016/bs.ai.2015.04.001
Chowell, D., Krishna, C., Pierini, F., Makarov, V., Rizvi, N. A., Kuo, F., et al. (2019). Evolutionary Divergence of HLA Class I Genotype Impacts Efficacy of Cancer Immunotherapy. Nat. Med. 25, 1715–1720. doi:10.1038/s41591-019-0639-4
Chumbley, G., King, A., Robertson, K., Holmes, N., and Loke, Y. W. (1994). Resistance of HLA-G and HLA-A2 Transfectants to Lysis by Decidual NK Cells. Cell Immunol. 155, 312–322. doi:10.1006/cimm.1994.1125
Colbern, G. T., Chiang, M. H., and Main, E. K. (1994). Expression of the Nonclassic Histocompatibility Antigen HLA-G by Preeclamptic Placenta. Am. J. Obstet. Gynecol. 170, 1244–1250. doi:10.1016/s0002-9378(13)90442-7
Colonna, M., Samaridis, J., Cella, M., Angman, L., Allen, R. L., O'Callaghan, C. A., et al. (1998). Human Myelomonocytic Cells Express an Inhibitory Receptor for Classical and Nonclassical MHC Class I Molecules. J. Immunol. 160, 3096–3100.
Crespo, Â. C., Strominger, J. L., and Tilburgs, T. (2016). Expression of KIR2DS1 by Decidual Natural Killer Cells Increases Their Ability to Control Placental HCMV Infection. Proc. Natl. Acad. Sci. U.S.A. 113, 15072–15077. doi:10.1073/pnas.1617927114
Ebrahimiadib, N., Berijani, S., Ghahari, M., and Pahlaviani, F. G. (2021). Ankylosing Spondylitis. J. Ophtalmic Vis. Res. 16, 462–469. doi:10.18502/jovr.v16i3.9440
Enczmann, J., Balz, V., Hoffmann, M., Kummer, S., Reinauer, C., Döing, C., et al. (2021). Next Generation Sequencing Identifies the HLA-Dqa1*03:03 Allele in the Type 1 Diabetes Risk-Associated HLA-DQ8 Serotype. Genes 12 (12), 1879. doi:10.3390/genes12121879
Felix, N. J., and Allen, P. M. (2007). Specificity of T-Cell Alloreactivity. Nat. Rev. Immunol. 7 (12), 942–953. doi:10.1038/nri2200
Fisher, S. J. (2015). Why Is Placentation Abnormal in Preeclampsia? Am. J. Obstet. Gynecol. 213, S115–S122. doi:10.1016/j.ajog.2015.08.042
Fons, P., Chabot, S., Cartwright, J. E., Lenfant, F., L'Faqihi, F., Giustiniani, J., et al. (2006). Soluble HLA-G1 Inhibits Angiogenesis through an Apoptotic Pathway and by Direct Binding to CD160 Receptor Expressed by Endothelial Cells. Blood 108, 2608–2615. doi:10.1182/blood-2005-12-019919
Fu, B., Zhou, Y., Ni, X., Tong, X., Xu, X., Dong, Z., et al. (2017). Natural Killer Cells Promote Fetal Development through the Secretion of Growth-Promoting Factors. Immunity 47 (6), 1100–1113. doi:10.1016/j.immuni.2017.11.018
Fujii, T., Ishitani, A., and Geraghty, D. E. (1994). A Soluble Form of the HLA-G Antigen Is Encoded by a Messenger Ribonucleic Acid Containing Intron 4. J. Immunol. 153, 5516–5524.
Gamliel, M., Goldman-Wohl, D., Isaacson, B., Gur, C., Stein, N., Yamin, R., et al. (2018). Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies. Immunity 48 (5), 951–962. doi:10.1016/j.immuni.2018.03.030
Garcia-Beltran, W. F., Hölzemer, A., Martrus, G., Chung, A. W., Pacheco, Y., Simoneau, C. R., et al. (2016). Open Conformers of HLA-F Are High-Affinity Ligands of the Activating NK-Cell Receptor KIR3DS1. Nat. Immunol. 17, 1067–1074. doi:10.1038/ni.3513
Gobin, S. J. P., and van den Elsen, P. J. (2000). Transcriptional Regulation of the MHC Class Ib Genes HLA-E, HLA-F, and HLA-G. Hum. Immunol. 61, 1102–1107. doi:10.1016/s0198-8859(00)00198-1
Goldman-Wohl, D. S., Ariel, I., and Greenfield, C. (2000). Lack of Human Leukocyte Antigen-G Expression in Extravillous Trophoblasts Is Associated with Pre-eclampsia. Mol. Hum. Reprod. 6, 88–95. doi:10.1093/molehr/6.1.88
Grant, E. J., Nguyen, A. T., Lobos, C. A., Szeto, C., Chatzileontiadou, D. S. M., and Gras, S. (2020). The Unconventional Role of HLA-E: the Road Less Traveled. Mol. Immunol. 120, 101–112. doi:10.1016/j.molimm.2020.02.011
Gundogan, F., Bianchi, D. W., Scherjon, S. A., and Roberts, D. J. (2010). Placental Pathology in Egg Donor Pregnancies. Fertil. Sterility 93, 397–404. doi:10.1016/j.fertnstert.2008.12.144
Guo, Y., Lee, C.-L., So, K.-H., Gao, J., Yeung, W. S. B., Yao, Y., et al. (2013). Soluble Human Leukocyte Antigen-G5 Activates Extracellular Signal-Regulated Protein Kinase Signaling and Stimulates Trophoblast Invasion. PLoS One 8 (10), e76023. doi:10.1371/journal.pone.0076023
Guzeloglu-Kayisli, O., Kayisli, U. A., and Taylor, H. S. (2009). The Role of Growth Factors and Cytokines during Implantation: Endocrine and Paracrine Interactions. Semin. Reprod. Med. 27 (1), 62–79. doi:10.1055/s-0028-1108011
Hackmon, R., Pinnaduwage, L., Zhang, J., Lye, S. J., Geraghty, D. E., and Dunk, C. E. (2017). Definitive Class I Human Leukocyte Antigen Expression in Gestational Placentation: HLA-F, HLA-E, HLA-C, and HLA-G in Extravillous Trophoblast Invasion on Placentation, Pregnancy, and Parturition. Am. J. Reprod. Immunol. 77 (6), e12643. doi:10.1111/aji.12643
Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield, C., Natanson-Yaron, S., et al. (2006). Decidual NK Cells Regulate Key Developmental Processes at the Human Fetal-Maternal Interface. Nat. Med. 12, 1065–1074. doi:10.1038/nm1452
Hara, N., Fujii, T., Yamashita, T., Kozuma, S., Okai, T., and Taketani, Y. (1996). Altered Expression of Human Leukocyte Antigen G (HLA-G) on Extravillous Trophoblasts in Preeclampsia: Immunohistological Demonstration with Anti-HLA-G Specific Antibody "87G" and Anti-cytokeratin Antibody "CAM5.2". Am. J. Reprod. Immunol. 36, 349–358. doi:10.1111/j.1600-0897.1996.tb00185.x
Hiby, S. E., Walker, J. J., O'Shaughnessy, K. M., Redman, C. W. G., Carrington, M., Trowsdale, J., et al. (2004). Combinations of Maternal KIR and Fetal HLA-C Genes Influence the Risk of Preeclampsia and Reproductive success. J. Exp. Med. 200, 957–965. doi:10.1084/jem.20041214
Hiby, S. E., Apps, R., Sharkey, A. M., Farrell, L. E., Gardner, L., Mulder, A., et al. (2010). Maternal Activating KIRs Protect against Human Reproductive Failure Mediated by Fetal HLA-C2. J. Clin. Invest. 120 (11), 4102–4110. doi:10.1172/jci43998
Hoff, C., Peevy, K., Giattina, K., Spinnato, J. A., and Peterson, R. D. (1992). Maternal-fetal HLA-DR Relationships and Pregnancy-Induced Hypertension. Obstet. Gynecol. 80 (6), 1007–1012.
Hviid, T. V., Rizzo, R., Christiansen, O. B., Melchiorri, L., Lindhard, A., and Baricordi, O. R. (2004). HLA-G and IL-10 in Serum in Relation to HLA-G Genotype and Polymorphisms. Immunogenetics 56, 135–141. doi:10.1007/s00251-004-0673-2
Hviid, T. V. F., Hylenius, S., Rørbye, C., and Nielsen, L. G. (2003). HLA-G Allelic Variants Are Associated with Differences in the HLA-G mRNA Isoform Profile and HLA-G mRNA Levels. Immunogenetics 55, 63–79. doi:10.1007/s00251-003-0547-z
Hylenius, S., Andersen, A. M., Melbye, M., and Hviid, T. V. (2004). Association between HLA-G Genotype and Risk of Pre-eclampsia: a Case-Control Study Using Family Triads. Mol. Hum. Reprod. 10, 237–246. doi:10.1093/molehr/gah035
Ishitani, A., and Geraghty, D. E. (1992). Alternative Splicing of HLA-G Transcripts Yields Proteins with Primary Structures Resembling Both Class I and Class II Antigens. Proc. Natl. Acad. Sci. U.S.A. 89, 3947–3951. doi:10.1073/pnas.89.9.3947
Ishitani, A., Sageshima, N., Lee, N., Dorofeeva, N., Hatake, K., Marquardt, H., et al. (2003). Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F, and G in Maternal-Placental Immune Recognition. J. Immunol. 171, 1376–1384. doi:10.4049/jimmunol.171.3.1376
Jakobsson, G. L., Stephansson, O., Askling, J., and Jacobsson, L. T. H. (2016). Pregnancy Outcomes in Patients with Ankylosing Spondylitis: a Nationwide Register Study. Ann. Rheum. Dis. 75, 1838–1842. doi:10.1136/annrheumdis-2015-207992
Kapasi, K., Albert, S. E., Yie, S.-M., Zavazava, N., and Librach, C. L. (2000). HLA-G Has a Concentration-dependent Effect on the Generation of an Allo-CTL Response. Immunology 101, 191–200. doi:10.1046/j.1365-2567.2000.00109.x
Kelemu, T., Erlandsson, L., Seifu, D., Hansson, E., Abebe, M., Teklu, S., et al. (2020). Polymorphism in Killer Cell Immunoglobulin-like Receptors and Human Leukocyte Antigen-C and Predisposition to Preeclampsia in Ethiopian Pregnant Women Population. J. Reprod. Immunol. 141, 103169. doi:10.1016/j.jri.2020.103169
Köstlin, N., Ostermeir, A.-L., Spring, B., Schwarz, J., Marmé, A., Walter, C. B., et al. (2017). HLA-G Promotes Myeloid-Derived Suppressor Cell Accumulation and Suppressive Activity during Human Pregnancy through Engagement of the Receptor ILT4. Eur. J. Immunol. 47, 374–384. doi:10.1002/eji.201646564
Langkilde, C. H., Nilsson, L. L., Jørgensen, N., Funck, T., Perin, T. L., Hornstrup, M. B., et al. (2020). Variation in the HLA-F Gene Locus with Functional Impact Is Associated with Pregnancy success and Time-To-Pregnancy after Fertility Treatment. Hum. Reprod 35 (3), 705–717. doi:10.1093/humrep/dez276
Larsen, T. G., Hackmon, R., Geraghty, D. E., and Hviid, T. V. F. (2019). Fetal Human Leukocyte Antigen-C and Maternal Killer-Cell Immunoglobulin-like Receptors in Cases of Severe Preeclampsia. Placenta 75, 27–33. doi:10.1016/j.placenta.2018.11.008
Lashley, E. E. L. O., Meuleman, T., and Claas, F. H. J. (2013). Beneficial or Harmful Effect of Antipaternal Human Leukocyte Antibodies on Pregnancy Outcome? A Systematic Review and Meta-Analysis. Am. J. Reprod. Immunol. 70, 87–103. doi:10.1111/aji.12109
Lashley, L. E. E. L. O., Haasnoot, G. W., Spruyt-Gerritse, M., and Claas, F. H. J. (2015). Selective Advantage of HLA Matching in Successful Uncomplicated Oocyte Donation Pregnancies. J. Reprod. Immunol. 112, 29–33. doi:10.1016/j.jri.2015.05.006
Le Gal, F.-A., Riteau, B., Sedlik, C., Khalil-Daher, I., Menier, C., Dausset, J., et al. (1999). HLA-G-mediated Inhibition of Antigen-specific Cytotoxic T Lymphocytes. Int. Immunol. 11, 1351–1356. doi:10.1093/intimm/11.8.1351
Leavey, K., Bainbridge, S. A., and Cox, B. J. (2015). Large Scale Aggregate Microarray Analysis Reveals Three Distinct Molecular Subclasses of Human Preeclampsia. PLoS ONE 10 (2), e0116508. doi:10.1371/journal.pone.0116508
Leavey, K., Benton, S. J., Grynspan, D., Kingdom, J. C., Bainbridge, S. A., and Cox, B. J. (2016). Unsupervised Placental Gene Expression Profiling Identifies Clinically Relevant Subclasses of Human Preeclampsia. Hypertension 68, 137–147. doi:10.1161/hypertensionaha.116.07293
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López-Botet, M., et al. (1998). HLA-E Is a Major Ligand for the Natural Killer Inhibitory Receptor CD94/NKG2A. Proc. Natl. Acad. Sci. U.S.A. 95, 5199–5204. doi:10.1073/pnas.95.9.5199
LeMaoult, J., Krawice-Radanne, I., Dausset, J., and Carosella, E. D. (2004). HLA-G1-expressing Antigen-Presenting Cells Induce Immunosuppressive CD4 + T Cells. Proc. Natl. Acad. Sci. U.S.A. 101, 7064–7069. doi:10.1073/pnas.0401922101
Lim, K. H., Zhou, Y., Janatpour, M., McMaster, M., Bass, K., Chun, S. H., et al. (1997). Human Cytotrophoblast Differentiation/invasion Is Abnormal in Pre-eclampsia. Am. J. Pathol. 151, 1809–1818.
Lissauer, D., Piper, K., Goodyear, O., Kilby, M. D., and Moss, P. A. H. (2012). Fetal-Specific CD8+Cytotoxic T Cell Responses Develop during Normal Human Pregnancy and Exhibit Broad Functional Capacity. J. Immunol. 189 (2), 1072–1080. doi:10.4049/jimmunol.1200544
Long, W., Shi, Z., Fan, S., Liu, L., Lu, Y., Guo, X., et al. (2015). Association of Maternal KIR and Fetal HLA-C Genes with the Risk of Preeclampsia in the Chinese Han Population. Placenta 36, 433–437. doi:10.1016/j.placenta.2014.05.008
Moffett, A., and Loke, C. (2006). Immunology of Placentation in Eutherian Mammals. Nat. Rev. Immunol. 6, 584–594. doi:10.1038/nri1897
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., et al. (1998). Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism. Science 281 (5380), 1191–1193. doi:10.1126/science.281.5380.1191
Nagamatsu, T., Schust, D. J., Sugimoto, J., and Barrier, B. F. (2009). Human Decidual Stromal Cells Suppress Cytokine Secretion by Allogenic CD4+ T Cells via PD-1 Ligand Interactions. Hum. Reprod. 24 (12), 3160–3171. doi:10.1093/humrep/dep308
Naiyer, M. M., Cassidy, S. A., Magri, A., Cowton, V., Chen, K., Mansour, S., et al. (2017). KIR2DS2 Recognizes Conserved Peptides Derived from Viral Helicases in the Context of HLA-C. Sci. Immunol. 2 (15), eaal5296. doi:10.1126/sciimmunol.aal5296
Nakimuli, A., Chazara, O., Hiby, S. E., Farrell, L., Tukwasibwe, S., Jayaraman, J., et al. (2015). A KIR B Centromeric Region Present in Africans but Not Europeans Protects Pregnant Women from Pre-eclampsia. Proc. Natl. Acad. Sci. U.S.A. 112, 845–850. doi:10.1073/pnas.1413453112
Neefjes, J., Jongsma, M. L. M., Paul, P., and Bakke, O. (2011). Towards a Systems Understanding of MHC Class I and MHC Class II Antigen Presentation. Nat. Rev. Immunol. 11 (12), 823–836. doi:10.1038/nri3084
Nilsson, L. L., Djurisic, S., Andersen, A.-M. N., Melbye, M., Bjerre, D., Ferrero-Miliani, L., et al. (2016). Distribution of HLA-G Extended Haplotypes and One HLA-E Polymorphism in a Large-Scale Study of Mother-Child Dyads with and without Severe Preeclampsia and Eclampsia. HLA 88, 172–186. doi:10.1111/tan.12871
O'Brien, M., McCarthy, T., Jenkins, D., Paul, P., Dausset, J., Carosella, E. D., et al. (2001). Altered HLA-G Transcription in Pre-eclampsia Is Associated with Allele Specific Inheritance: Possible Role of the HLA-G Gene in Susceptibility to the Disease. Cell. Mol. Life Sci. 58, 1943–1949. doi:10.1007/PL00000828
Pabalan, N., Jarjanazi, H., Sun, C., and Iversen, A. C. (2015). Meta-analysis of the Human Leukocyte Antigen-G (HLA-G) 14 Bp Insertion/deletion Polymorphism as a Risk Factor for Preeclampsia. Tissue Antigens 86, 186–194. doi:10.1111/tan.12627
Parham, P. (2005). MHC Class I Molecules and KIRs in Human History, Health and Survival. Nat. Rev. Immunol. 5, 201–214. doi:10.1038/nri1570
Payne, R., and Rolfs, M. R. (1958). Fetomaternal Leukocyte Incompatibility12. J. Clin. Invest. 37, 1756–1763. doi:10.1172/jci103768
Pazmany, L., Mandelboim, O., Valés-Gómez, M., Davis, D. M., Reyburn, H. T., and Strominger, J. L. (1996). Protection from Natural Killer Cell-Mediated Lysis by HLA-G Expression on Target Cells. Science 274, 792–795. doi:10.1126/science.274.5288.792
Persson, G., Jørgensen, N., Nilsson, L. L., Andersen, L. H. J., and Hviid, T. V. F. (2020). A Role for Both HLA-F and HLA-G in Reproduction and during Pregnancy? Hum. Immunol. 81, 127–133. doi:10.1016/j.humimm.2019.09.006
Rajagopalan, S., Bryceson, Y. T., Kuppusamy, S. P., Geraghty, D. E., van der Meer, A., Joosten, I., et al. (2006). Activation of NK Cells by an Endocytosed Receptor for Soluble HLA-G. Plos Biol. 4 (1), e9. doi:10.1371/journal.pbio.0040009
Rajagopalan, S., and Long, E. O. (1999). A Human Histocompatibility Leukocyte Antigen (HLA)-G-specific Receptor Expressed on All Natural Killer Cells. J. Exp. Med. 189, 1093–1100. doi:10.1084/jem.189.7.1093
Roberts, J. M., Rich-Edwards, J. W., McElrath, T. F., Garmire, L., and Myatt, L. (2021). Global Pregnancy collaborationSubtypes of Preeclampsia: Recognition and Determining Clinical Usefulness. Hypertension 77, 1430–1441. doi:10.1161/hypertensionaha.120.14781
Robinson, J., Halliwell, J. A., McWilliam, H., Lopez, R., and Marsh, S. G. (2013). IPD--the Immuno Polymorphism Database. Nucleic Acids Res. 41, D1234–D1240. doi:10.1093/nar/gks1140
Robinson, J., Barker, D. J., Georgiou, X., Cooper, M. A., Flicek, P., and Marsh, S. G. E. (2020). IPD-IMGT/HLA Database. Nucleic Acids Res. 48, D948–D955. doi:10.1093/nar/gkz950
Rokhafrooz, S., Ghadiri, A., Ghandil, P., Ghafourian, M., Hossaini, S. H., Daraei, N., et al. (2018). Association between HLA-G 14bp Gene Polymorphism and Serum sHLA-G Protein Concentrations in Preeclamptic Patients and normal Pregnant Women. Immunological Invest. 47, 558–568. doi:10.1080/08820139.2018.1467925
Romero, R., Whitten, A., Korzeniewski, S. J., Than, N. G., Chaemsaithong, P., Miranda, J., et al. (2013). Maternal Floor Infarction/massive Perivillous Fibrin Deposition: a Manifestation of Maternal Antifetal Rejection? Am. J. Reprod. Immunol. 70, 285–298. doi:10.1111/aji.12143
Rouas-Freiss, N., Gonçalves, R. M.-B., Menier, C., Dausset, J., and Carosella, E. D. (1997). Direct Evidence to Support the Role of HLA-G in Protecting the Fetus from Maternal Uterine Natural Killer Cytolysis. Proc. Natl. Acad. Sci. U.S.A. 94, 11520–11525. doi:10.1073/pnas.94.21.11520
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., and Ohkura, N. (2020). Regulatory T Cells and Human Disease. Annu. Rev. Immunol. 38, 541–566. doi:10.1146/annurev-immunol-042718-041717
Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A.-B., Daniels, J., et al. (2014). Global Causes of Maternal Death: a WHO Systematic Analysis. Lancet Glob. Health 2 (6), e323–e333. doi:10.1016/s2214-109x(14)70227-x
Schonkeren, D., Swings, G., Roberts, D., Claas, F., de Heer, E., and Scherjon, S. (2012). Pregnancy Close to the Edge: an Immunosuppressive Infiltrate in the Chorionic Plate of Placentas from Uncomplicated Egg Cell Donation. PLoS ONE 7 (3), e32347. doi:10.1371/journal.pone.0032347
Selvaraja, M., Too, C. L., Tan, L. K., Koay, B. T., Abdullah, M., Shah, A. M., et al. (2022). Human Leucocyte Antigens Profiling in Malay Female Patients with Systemic Lupus Erythematosus: Are We the Same or Different? Lupus Sci. Med. 9 (1), e000554. doi:10.1136/lupus-2021-000554
Shiina, T., Hosomichi, K., Inoko, H., and Kulski, J. K. (2009). The HLA Genomic Loci Map: Expression, Interaction, Diversity and Disease. J. Hum. Genet. 54, 15–39. doi:10.1038/jhg.2008.5
Shiroishi, M., Kuroki, K., Ose, T., Rasubala, L., Shiratori, I., Arase, H., et al. (2006). Efficient Leukocyte Ig-like Receptor Signaling and crystal Structure of Disulfide-Linked HLA-G Dimer. J. Biol. Chem. 281, 10439–10447. doi:10.1074/jbc.m512305200
Shobu, T., Sageshima, N., Tokui, H., Omura, M., Saito, K., Nagatsuka, Y., et al. (2006). The Surface Expression of HLA-F on Decidual Trophoblasts Increases from Mid to Term Gestation. J. Reprod. Immunol. 72, 18–32. doi:10.1016/j.jri.2006.02.001
Sidney, J., Peters, B., Frahm, N., Brander, C., and Sette, A. (2008). HLA Class I Supertypes: a Revised and Updated Classification. BMC Immunol. 9, 1. doi:10.1186/1471-2172-9-1
Sim, M. J. W., Rajagopalan, S., Altmann, D. M., Boyton, R. J., Sun, P. D., and Long, E. O. (2019). Human NK Cell Receptor KIR2DS4 Detects a Conserved Bacterial Epitope Presented by HLA-C. Proc. Natl. Acad. Sci. U.S.A. 116, 12964–12973. doi:10.1073/pnas.1903781116
Small, H. Y., Akehurst, C., Sharafetdinova, L., McBride, M. W., McClure, J. D., Robinson, S. W., et al. (2017). HLA Gene Expression Is Altered in Whole Blood and Placenta from Women Who Later Developed Preeclampsia. Physiol. Genomics 49, 193–200. doi:10.1152/physiolgenomics.00106.2016
Solier, C., Aguerre-Girr, M., Lenfant, F. o., Campan, A. s., Berrebi, A., Rebmann, V., et al. (2002). Secretion of Pro-apoptotic Intron 4-retaining Soluble HLA-G1 by Human Villous Trophoblast. Eur. J. Immunol. 32, 3576–3586. doi:10.1002/1521-4141(200212)32:12<3576::aid-immu3576>3.0.co;2-m
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., and Mach, B. (1994). Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA. Science 265 (5168), 106–109. doi:10.1126/science.8016643
Steinborn, A., Varkonyi, T., Scharf, A., Bahlmann, F., Klee, A., and Sohn, C. (2007). Early Detection of Decreased Soluble HLA-G Levels in the Maternal Circulation Predicts the Occurrence of Preeclampsia and Intrauterine Growth Retardation during Further Course of Pregnancy. Am. J. Reprod. Immunol. 57, 277–286. doi:10.1111/j.1600-0897.2007.00475.x
Strong, R. K., Holmes, M. A., Li, P., Braun, L., Lee, N., and Geraghty, D. E. (2003). HLA-E Allelic Variants. J. Biol. Chem. 278, 5082–5090. doi:10.1074/jbc.m208268200
Svensson-Arvelund, J., Mehta, R. B., Lindau, R., Mirrasekhian, E., Rodriguez-Martinez, H., Berg, G., et al. (2015). The Human Fetal Placenta Promotes Tolerance against the Semiallogeneic Fetus by Inducing Regulatory T Cells and Homeostatic M2 Macrophages. J. Immunol. 194, 1534–1544. doi:10.4049/jimmunol.1401536
Tang, Y., Liu, H., Li, H., Peng, T., Gu, W., and Li, X. (2015). Hypermethylation of the HLA-G Promoter Is Associated with Preeclampsia. Mol. Hum. Reprod. 21, 736–744. doi:10.1093/molehr/gav037
Tersigni, C., Redman, C. W., Dragovic, R., Tannetta, D., Scambia, G., Di Simone, N., et al. (2018). HLA-DR Is Aberrantly Expressed at Feto-Maternal Interface in Pre-eclampsia. J. Reprod. Immunol. 129, 48–52. doi:10.1016/j.jri.2018.06.024
Tilburgs, T., Scherjon, S. A., van der Mast, B. J., Haasnoot, G. W., Versteeg-v.d.Voort-Maarschalk, M., Roelen, D. L., et al. (2009). Fetal-maternal HLA-C Mismatch Is Associated with Decidual T Cell Activation and Induction of Functional T Regulatory Cells. J. Reprod. Immunol. 82 (2), 148–157. doi:10.1016/j.jri.2009.05.003
Tilburgs, T., Schonkeren, D., Eikmans, M., Nagtzaam, N. M., Datema, G., Swings, G. M., et al. (2010). Human Decidual Tissue Contains Differentiated CD8+Effector-Memory T Cells with Unique Properties. J. Immunol. 185 (7), 4470–4477. doi:10.4049/jimmunol.0903597
Tilburgs, T., Crespo, Â. C., van der Zwan, A., Rybalov, B., Raj, T., Stranger, B., et al. (2015). Human HLA-G+ Extravillous Trophoblasts: Immune-Activating Cells that Interact with Decidual Leukocytes. Proc. Natl. Acad. Sci. U.S.A. 112, 7219–7224. doi:10.1073/pnas.1507977112
Triche, E. W., Harland, K. K., Field, E. H., Rubenstein, L. M., and Saftlas, A. F. (2014). Maternal-fetal HLA Sharing and Preeclampsia: Variation in Effects by Seminal Fluid Exposure in a Case-Control Study of Nulliparous Women in Iowa. J. Reprod. Immunol. 101-102, 111–119. doi:10.1016/j.jri.2013.06.004
Tsuda, S., Nakashima, A., Morita, K., Shima, T., Yoneda, S., Kishi, H., et al. (2021). The Role of Decidual Regulatory T Cells in the Induction and Maintenance of Fetal Antigen-specific Tolerance: Imbalance between Regulatory and Cytotoxic T Cells in Pregnancy Complications. Hum. Immunol. 82, 346–352. doi:10.1016/j.humimm.2021.01.019
van 't Hof, L. J., Schotvanger, N., Haasnoot, G. W., van der Keur, C., Roelen, D. L., Lashley, L. E. E. L. O., et al. (2021). Maternal-fetal HLA Compatibility in Uncomplicated and Preeclamptic Naturally Conceived Pregnancies. Front. Immunol. 12, 673131. doi:10.3389/fimmu.2021.673131
van Bentem, K., Bos, M., van der Keur, C., Brand-Schaaf, S. H., Haasnoot, G. W., Roelen, D. L., et al. (2020). The Development of Preeclampsia in Oocyte Donation Pregnancies Is Related to the Number of Fetal-Maternal HLA Class II Mismatches. J. Reprod. Immunol. 137, 103074. doi:10.1016/j.jri.2019.103074
van der Zwan, A., Bi, K., Norwitz, E. R., Crespo, Â. C., Claas, F. H. J., Strominger, J. L., et al. (2018). Mixed Signature of Activation and Dysfunction Allows Human Decidual CD8 + T Cells to Provide Both Tolerance and Immunity. Proc. Natl. Acad. Sci. U.S.A. 115 (2), 385–390. doi:10.1073/pnas.1713957115
Van Rood, J. J., Eernisse, J. G., and Van Leeuwen, A. (1958). Leucocyte Antibodies in Sera from Pregnant Women. Nature 181, 1735–1736. doi:10.1038/1811735a0
Vianna, P., Mondadori, A. G., Bauer, M. E., Dornfeld, D., and Chies, J. A. B. (2016). HLA-G and CD8+ Regulatory T Cells in the Inflammatory Environment of Pre-eclampsia. Reproduction 152, 741–751. doi:10.1530/rep-15-0608
Wedenoja, S., Yoshihara, M., Teder, H., Sariola, H., Gissler, M., Katayama, S., et al. (2020). Fetal HLA-G Mediated Immune Tolerance and Interferon Response in Preeclampsia. EBioMedicine 59, 102872. doi:10.1016/j.ebiom.2020.102872
Xiong, S., Sharkey, A. M., Kennedy, P. R., Gardner, L., Farrell, L. E., Chazara, O., et al. (2013). Maternal Uterine NK Cell-Activating Receptor KIR2DS1 Enhances Placentation. J. Clin. Invest. 123, 4264–4272. doi:10.1172/jci68991
Keywords: pregnancy, preeclampsia, HLA, HLA-G, HLA-C
Citation: Aisagbonhi O and Morris GP (2022) Human Leukocyte Antigens in Pregnancy and Preeclampsia. Front. Genet. 13:884275. doi: 10.3389/fgene.2022.884275
Received: 26 February 2022; Accepted: 29 March 2022;
Published: 27 April 2022.
Edited by:
Divyansh Agarwal, Massachusetts General Hospital, Harvard Medical School, United StatesReviewed by:
Frans H.J. Claas, Leiden University Medical Center, NetherlandsA. Inkeri Lokki, University of Helsinki, Finland
Eric T Weimer, University of North Carolina at Chapel Hill, United States
Copyright © 2022 Aisagbonhi and Morris. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Omonigho Aisagbonhi, oaisagbonhi@health.ucsd.edu; Gerald P. Morris, gpmorris@health.ucsd.edu